Biotechnology

ASCLETIS-B

Galore Pharma Reports ASC30 Phase 2 Study Results and Plans to Speak at ADA Scientific Sessions

Galore Pharmaceuticals-B Completes Phase II Study Enrollment for ASC30 in Type 2 Diabetes

Galore Pharma Plans to Submit ASC30_39 Obesity Drug IND Application

Galore Pharmaceutical Selects Oral Obesity Drug Combination for Clinical Development

ASCLETIS-B released FY2025 Q3 earnings on March 31, 2026 (BJT) with actual revenue of HKD 517.61 K and EPS of HKD -0.1513

ASCLETIS-B released FY2025 9 Months Earnings on March 31, 2026 (BJT), with actual revenue of HKD 1.688 M and EPS of HKD -0.2502

GALIRA BIOPHARMA-B Reports Increased Revenue and Widening Loss in 2025

ASCLETIS-B released FY2025 annual earnings on March 31 After-Market BJT, actual revenue HKD 2.217 M (forecast HKD 856.54 K), actual EPS HKD -0.4044 (forecast HKD -0.385)

ASCLETIS-B released FY2025 Q4 earnings on March 31 After-Market (BJT), actual revenue HKD 526.55 K, actual EPS HKD -0.1538

ASCLETIS-B to Release FY2025 Earnings on March 31 After-Market (BJT), Forecast Revenue HKD 876.49 K, EPS HKD -0.3939

GalaCell Pharmaceuticals Plans to Submit ASC39 NDA to FDA in Q3 2026

Got peer ASC30 Obesity Indication Study Yields Positive Results

GALAY BIOPHARMA Selects ASC36 for Clinical Development

GIC Private Limited Invests in GS Pharma-B

Galore Pharmaceutical-B Plans to Issue Shares to Raise Funds for Phase III Clinical Trials

Galore Pharmaceutical-B's ASC40 Phase III Clinical Trial for Acne Shows Positive Results

Gspt Biopharma Initiates Phase 2 Clinical Trial for ASC30

Galore Pharmaceutical Develops New Drug ASC37

Ascletis Pharma Receives FDA Approval for ASC30 Phase II Clinical Trial for Type 2 Diabetes

Galore Pharmaceuticals-B Repurchased 200,000 Shares

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

Genscript Biotech Corporation (1672.HK) 2025 Annual Performance Conference Call

Gere Pharmaceutical (1672.HK) 2025 Mid-Year Performance Conference Call

01672

Ascletis Pharma Inc. will present multiple programs at the 33rd European Congress on Obesity (ECO 2026) in Istanbul from May 12-15, 2026. Key presentations include Phase I data on ASC47, showing up to 111.8% greater weight loss when combined with semaglutide, and preclinical data on ASC36, demonstrating a 32-day half-life and significant weight loss in animal models. The company focuses on developing innovative therapeutics for metabolic diseases and is listed on the Hong Kong Stock Exchange.

prnewswire

20:10 ETAscletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)

Ascletis Pharma Inc. (HKEX: 1672) will present multiple programs at the American Diabetes Association's 2026 Scientific Sessions from June 5-8, 2026, in New Orleans. Key presentations include a late-breaking poster on ASC39, an oral amylin receptor agonist for obesity, and findings on ASC30 and ASC37, both aimed at weight management. Ascletis focuses on developing innovative therapeutics for metabolic diseases using advanced drug discovery technologies.

20:10 ETAscletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions

Ascletis Pharma (SEHK:1672) has selected its ASC30_39 obesity therapy candidate for clinical development, planning to file an IND with the U.S. FDA by Q3 2026. The company's shares have risen 25.03% over the past 30 days, with a current price of HK$18.48, but it trades at a high P/B ratio of 8.8x, above the industry average of 5.3x, indicating potential overvaluation. Despite ongoing losses of CN¥359.88m and limited revenue, market expectations remain high. Investors are advised to consider risks and explore other investment opportunities.

Simplywall

Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing

513700

00460

513120

Hong Kong's innovative drug sector is experiencing significant growth, with companies like Ascletis Pharmaincreasing over 3% and Hansoh Pharmaceuticalrising by more than 2%. Other firms, including WuXi AppTecand Sihuan Pharmaceutical, are also showing upward trends.

CoinLive

Penghua CSI HK Connect Health Care Composite ETF

SIHUAN PHARM

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

HANSOH PHARMA

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

WUXI APPTEC

Hong Kong's Innovative Drug Sector Gains Momentum

Ascletis Pharma, Inc. (HK:1672) is advancing its fixed-dose oral obesity pill, ASC30_39 FDC, toward a U.S. FDA Investigational New Drug application planned for Q3 2026. This combination of GLP-1 receptor agonist ASC30 and amylin-selective receptor agonist ASC39 aims to enhance patient convenience with a once-daily regimen. Preclinical studies show promising results in terms of bioavailability and tolerability. The stock currently holds a Hold rating with a price target of HK$13.50, and the company focuses on innovative therapies for metabolic diseases.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026

00799

02291

02650

02477

00586

03320

02157

02197

03888

IGG(00799) rose 20.88%, with a trading turnover 46.7 Million HKD, and a year-to-date fell 5.8%. ASCLETIS-B(01672) rose 12.67%, with a trading turnover 147.1 Million HKD, and a year-to-date rose 42.8%. SCIENTECH(02291) rose 11.13%, with a trading turnover 151.8 Million HKD, and a year-to-date fell 1.9%.

Top Gainers&Losers

SCIENTECH

ZHIDA TECH

WELLCELL HOLD

CONCH VENTURE

CHINARES PHARMA

LEPU BIO

CLOVER BIO-B

KINGSOFT

Top 10 HK Stock Gainers (3.26)

516500

159102

Hong Kong's biopharmaceutical sector saw significant stock gains amid market volatility, with XuanZhu Biopharma-Brising over 12%, Ascletis Pharmaincreasing by more than 7%, and both Lepu Biopharmaand XtalPi Holdingsclimbing over 6%. Akeso Biopharmaalso saw a rise of 5.5%. This trend indicates a positive outlook for the biopharmaceutical industry in Hong Kong's stock market.

ASCLETIS-B(01672.HK)